ClinicalTrials.gg
TerminatedNCT01067352SAIZEN in SGAUpdated Dec 27, 2013Results posted

A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

A Phase 3 interventional study of Recombinant human growth hormone (r-hGH) in Infant, Small for Gestational Age, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Italy. Open to participants aged 4 Years to 6 Years. Per ClinicalTrials.gov, last updated 2013-12-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Why this study was terminated
This study was discontinued prematurely due to difficulty in participant recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
4 Years to 6 Years
Sex
All
01

Study summary

This open, multicentric, randomized, controlled study is planned to evaluate the correlation between gene expression, spontaneous catch-up growth and therapeutic response to Saizen in SGA children.

Read the detailed description

This open, multicentric, randomized, controlled study was planned to identify genes activated by hGH in SGA children responders to treatment (making it possible in the near future to better identify SGA children likely to benefit from hGH treatment). Furthermore, the study would hopefully allow to verify which genes were responsible of spontaneous catch-up growth in children with diagnosis of SGA at birth but above the third percentile for height at the age of 24 months, and if these genes were the same activated by hGH during the treatment in participants responders. Sixty children born at term (i.e. after the 37th completed week of gestation) and with a diagnosis of SGA (defined as a length less than tenth percentile according to the Italian reference table published by Bertini and Fabris) were planned to be enrolled in the study. Forty participants (group A) were still less than third percentile for height (according to the Tanner reference table) at the age of 24 months, the remaining 20 (group B) being more than or equal to third percentile (thus showing a spontaneous catch-up growth). Group A was randomized to receive Saizen at the daily dose of 0.067 mg/kg (Group A1) or no treatment (Group A2) for two years. All participants were to undergo full clinical examination and blood chemistry at baseline visit and visit after 1,6,12,18 and 24 months for a period of two years. Gene expression analysis using the Clontech Atlas Human Array was performed in all participants at baseline and after one year in order to identify the possible correlation between catch-up growth (either spontaneous or drug-induced) and expression of some genes.

OBJECTIVES

Primary objective:

  • To evaluate the correlation between gene expression profiling and catch-up growth (either spontaneous or drug induced after one year of treatment) in SGA children.

Secondary Objectives:

  • To evaluate the percentage of participants not treated who show a spontaneous catch-up growth during the two years of observation.
  • To assess the safety and tolerability of early treatment with Saizen
02

Conditions studied

  • Infant, Small for Gestational Age

Keywords

  • Infant, small for gestational age
  • Growth hormone
  • Saizen
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SGA at birth (defined as a length at birth equal or below the tenth percentile according to the Italian reference table of Bertini and Fabris)
  • Age of 24 Months
  • Caucasic
  • Born at term (i.e. after the 37th completed week of gestation)
  • Height equal or below (Group A) or up (Group B) the third percentile at the age of 24 months according to the Tanner reference table
  • Sufficient GH secretion (more than 10 nanogram (ng)/milliliter (ml)) at least to one of the tests commonly used at that age (glucagon, Levo-dopa, arginine, clonidine, Growth Hormone Releasing Hormone (GHRH), GH integrated secretion)
  • Normal level of Thyroid-stimulating hormone (THS), Free Triiodothyronine (FT3), Free Thyroxine (FT4), Insulin-like growth factor 1(IGF-1), insulin and (HbA1c)
  • Normal level of Immunoglobulin A (IgA)
  • Children parents willing to comply with the protocol for the whole duration of the study
  • A written before the baseline visit must be obtained from the parent(s) / legal guardian(s)

Exclusion criteria

Exclusion Criteria:

  • Congenital malformations (including Silver-Russel syndrome)
  • Known abnormal karyotype, especially in girls
  • Twins
  • Severe psychomotor retardation
  • Previous or ongoing treatment with anabolic steroids or r-hGH
  • Treatments interfering with the immune system (including bacterial lysate)
  • Severe chronic illnesses
  • diseases
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Group A (A1)

    Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.

    Drug: Recombinant human growth hormone (r-hGH)

  • No intervention
    Group A (A2)

    Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.

  • No intervention
    Group B

    Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).

Interventions

06

What researchers measure

Primary outcomes

  1. Correlation Between Gene Expression Profiling and Catch-up Growth in Small for Gestational Age (SGA) Children

    Gene expression profiling:analysis of ribonucleic acid (RNA) extracted from body tissue or fluids using Clontech Atlas Human Array to study level of activation of genes in tissue analyzed. Analysis was performed to identify possible correlation between catch-up growth (either spontaneous or drug-induced after Week 48) and therapeutic response to rhGH. Spontaneous catch up growth:shown by SGA participants having length more than third percentile at Week 96 without any treatment;drug induced growth was by SGA participants having length more than third percentile at Week 96 with drug treatment.

    Time frame: Baseline and Week 48

Secondary outcomes

  1. Percentage of Untreated Participants Who Showed a Spontaneous Catch-up Growth

    Spontaneous catch up growth was the growth shown by SGA participants having length more than third percentile at Week 96 without any study drug treatment.

    Time frame: Baseline through Week 96

  2. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation

    AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug , SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.

    Time frame: Baseline through Week 96

07

Results

Posted Dec 14, 2011
Limitations and caveats
The primary and secondary efficacy objectives were not met because of poor participant enrollment and no quality RNA samples obtained to evaluate (RNA degradation in nearly all of the blood samples).

Participant flow

Participants were recruited in 12 study centers in Italy from 20 Feb 2004 to 10 Jul 2009.

Participant flow — Overall Study
MilestoneGroup A, Less Than Third Percentile (Saizen)Group A2, Less Than Third Percentile (No Treatment)Group B, More Than Third Percentile (No Treatment)
Started9610
Completed839
Not completed131
Withdrew: Withdrawal by subject121
Withdrew: Physician decision010

Outcome measures

PrimaryCorrelation Between Gene Expression Profiling and Catch-up Growth in Small for Gestational Age (SGA) Children

Gene expression profiling:analysis of ribonucleic acid (RNA) extracted from body tissue or fluids using Clontech Atlas Human Array to study level of activation of genes in tissue analyzed. Analysis was performed to identify possible correlation between catch-up growth (either spontaneous or drug-induced after Week 48) and therapeutic response to rhGH. Spontaneous catch up growth:shown by SGA participants having length more than third percentile at Week 96 without any treatment;drug induced growth was by SGA participants having length more than third percentile at Week 96 with drug treatment.

Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondaryPercentage of Untreated Participants Who Showed a Spontaneous Catch-up Growth

Spontaneous catch up growth was the growth shown by SGA participants having length more than third percentile at Week 96 without any study drug treatment.

Time frame:
Baseline through Week 96

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation

AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug , SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.

Time frame:
Baseline through Week 96
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation
participantsGroup A, Less Than Third Percentile (Saizen)Group A2, Less Than Third Percentile (No Treatment)Group B, More Than Third Percentile (No Treatment)
AEs649
SAEs000
Discontinuation due to AEs000

Adverse events

Collected over AEs were collected on an ongoing basis from day of written informed consent. All new AEs were recorded until the post-treatment safety, on Day 30 post-drug administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A, Less Than Third Percentile (Saizen)—0/8 (0%)6/8 (75%)
Group A2, Less Than Third Percentile (No Treatment)—0/4 (0%)4/4 (100%)
Group B, More Than Third Percentile (No Treatment)—0/10 (0%)9/10 (90%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventGroup A, Less Than Third Percentile (Saizen)Group A2, Less Than Third Percentile (No Treatment)Group B, More Than Third Percentile (No Treatment)
PyrexiaGeneral disorders6/82/44/10
PharyngitisInfections and infestations1/82/42/10
VaricellaInfections and infestations0/82/42/10
BronchitisInfections and infestations2/81/43/10
InfluenzaInfections and infestations0/80/43/10
DiarrhoeaGastrointestinal disorders0/81/40/10
GastroenteritisInfections and infestations0/81/40/10
TonsillitisInfections and infestations0/81/41/10
Blood alkaline phosphatase increasedInvestigations0/81/40/10
Blood cholesterol increasedInvestigations0/81/40/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group A, Less Than Third Percentile (Saizen)Group A2, Less Than Third Percentile (No Treatment)Group B, More Than Third Percentile (No Treatment)Total
Mean5.7 ± 1.25.0 ± 0.75.2 ± 0.45.3 ± 0.9
Sex: Female, Male
Sex: Female, Male(Participants)Group A, Less Than Third Percentile (Saizen)Group A2, Less Than Third Percentile (No Treatment)Group B, More Than Third Percentile (No Treatment)Total
Female44513
Male52512
08

Study locations

1 site
  • Merck Serono S.p.A.
    Roma, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2010
First posted
Feb 11, 2010
Start
Feb 2004
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Dec 14, 2011
Last update
Dec 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01067352
Collaborators
Merck Serono S.P.A., Italy
Responsible party
Sponsor
First posted
Feb 11, 2010
Start date
Feb 2004
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Dec 14, 2011
Last update
Dec 27, 2013

Study contacts

Medical Responsible
study director · Merck Serono S.P.A., Italy
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion